Clinical Trial Update: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating Sunvozertinib in combination with Anlotinib as first-line treatment for EGFR-mutant advanced non-small cell lung cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING